ADAM9 (a disintegrin and metalloproteinase 9) is overexpressed in several gastrointestinal cancers, with expression levels correlating with suppressive tumor microenvironment, metastasis and poor prognosis. DB-1317, under development at Duality Biologics (Suzhou) Co. Ltd., is an ADAM9-targeting antibody-drug conjugate including a topoisomerase inhibitor payload P1003 at a drug-antibody ratio of 8.